诺瓦瓦克斯医药(NVAX)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

NVAX 诺瓦瓦克斯医药

盘后交易 06-09 18:17:20 EDT

8.67

+0.05

+0.58%

盘后8.65

-0.02-0.23%

18:12 EDT

最高8.86	最低8.35	成交量458.57万
今开8.75	昨收8.62	日振幅5.92%
总市值14.26亿	流通市值11.85亿	总股本1.64亿
成交额3,933万	换手率3.35%	流通股本1.37亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

{"stockData":{"symbol":"NVAX","market":"US","secType":"STK","nameCN":"诺瓦瓦克斯医药","latestPrice":8.67,"timestamp":1781035200000,"preClose":8.62,"halted":0,"volume":4585678,"hourTrading":{"tag":"盘后","latestPrice":8.65,"preClose":8.67,"latestTime":"18:12 EDT","volume":132382,"amount":1148971.773939,"timestamp":1781043169639,"change":-0.02,"changeRate":-0.002307,"amplitude":0.018454},"delay":0,"changeRate":0.005800464037123053,"floatShares":136723812,"shares":164427429,"eps":-0.5784,"marketStatus":"盘后交易","change":0.05,"latestTime":"06-09 18:17:20 EDT","open":8.75,"high":8.86,"low":8.35,"amount":39325407.995955996,"amplitude":0.059165,"askPrice":8.85,"askSize":670,"bidPrice":8.43,"bidSize":707,"shortable":3,"etf":0,"ttmEps":-0.5784,"tradingStatus":3,"nextMarketStatus":{"tag":"收盘","tradingStatus":0,"beginTime":1781049600000},"marketStatusCode":4,"adr":0,"adrRate":0,"exchange":"NASDAQ","adjPreClose":8.62,"preHourTrading":{"tag":"盘前","latestPrice":8.75,"preClose":8.62,"latestTime":"09:29 EDT","volume":24907,"amount":218459.521163,"timestamp":1781011741098,"change":0.13,"changeRate":0.015081,"amplitude":0.025325},"postHourTrading":{"tag":"盘后","latestPrice":8.65,"preClose":8.67,"latestTime":"18:12 EDT","volume":132382,"amount":1148971.773939,"timestamp":1781043169639,"change":-0.02,"changeRate":-0.002307,"amplitude":0.018454},"volumeRatio":0.938143,"impliedVol":0.7509,"impliedVolPercentile":0.1673},"requestUrl":"/m/hq/s/NVAX","defaultTab":"news","newsList":[{"id":"1139235440","title":"美国FDA顾问投票支持建议2026-27年度新冠疫苗以Jn.1谱系Xfg变异株为靶点","url":"https://stock-news.laohu8.com/highlight/detail?id=1139235440","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1139235440?lang=zh_cn&edition=full","pubTime":"2026-05-29 02:28","pubTimestamp":1779992883,"startTime":"0","endTime":"0","summary":"美国食品药品监督管理局的疫苗顾问小组已投票支持一项建议，即在2026-2027年度的新冠疫苗接种活动中，应将疫苗的靶点更新为当前流行的Jn.1谱系Xfg变异株。这一决定标志着公共卫生机构在应对病毒持续演变方面迈出了关键一步。相关企业可能需要据此调整其疫苗成分，以符合新的公共卫生指导。随着病毒变异，疫苗的定期更新已成为新常态，以确保其防护效力。最终决定权仍在FDA，但通常其会采纳顾问委员会的建议。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1066051498.USD","LU0306806265.USD","LU0321505868.SGD","LU0456855351.SGD","IE00B19Z3B42.SGD","IE00BLSP4239.USD","LU0225771236.USD","BK4581","LU1894683264.USD","SG9999002232.USD","SG9999013999.USD","LU0170899867.USD","IE000M9KFDE8.USD","LU0122379950.USD","LU0234572021.USD","BK4592","BK4550","LU1066053197.SGD","IE00B19Z3581.USD","SG9999001176.USD","BK4007","LU0321505439.SGD","SGXZ57979304.SGD","BK4532","SG9999002224.SGD","SG9999003800.SGD","LU0985481810.HKD","IE00BBT3K403.USD","PFE","IE0002270589.USD","LU1883839398.USD","BK4501","BK4568","MRNY","SG9999001176.SGD","BK4534","BK4599","LU1023059063.AUD","NVAX","BK4551","BK4588","LU0868494617.USD","IE00BLSP4452.SGD","LU1057294990.SGD","MRNX","LU1894683348.USD","SG9999011175.SGD","BK4547","BK4548","LU0225284248.USD","MRNA","LU0058720904.USD","LU0306807586.USD","LU0289739699.SGD","BK4139","BK4533","IE00B3T34201.USD","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1129861349","title":"赛诺菲宣布将Xfg蛋白Nuvaxovid疫苗作为其2026-27年度全球唯一新冠产品进行生产","url":"https://stock-news.laohu8.com/highlight/detail?id=1129861349","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1129861349?lang=zh_cn&edition=full","pubTime":"2026-05-28 20:21","pubTimestamp":1779970899,"startTime":"0","endTime":"0","summary":"赛诺菲在简报文件中表示，已确定将Xfg蛋白Nuvaxovid疫苗作为公司在2026-27年度全球范围内唯一的新冠疫苗产品进行生产制造。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BK4568","BK4588","GCVRZ","BK4585","NVAX","BK4547"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1195543647","title":"异动解读 | FDA探讨更新新冠疫苗针对XFG变异株，诺瓦瓦克斯医药盘中大涨12.54%","url":"https://stock-news.laohu8.com/highlight/detail?id=1195543647","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1195543647?lang=zh_cn&edition=full","pubTime":"2026-05-26 23:35","pubTimestamp":1779809715,"startTime":"0","endTime":"0","summary":"诺瓦瓦克斯医药(NVAX)今日盘中大涨12.54%，引起了市场的广泛关注。消息面上，美国食品药品监督管理局(FDA)顾问委员会将讨论是否应在2026-27年度的免疫接种活动中，对新冠疫苗进行更新，以针对目前流行的XFG亚型变异株。FDA表示，疫苗制造商已表示准备为2026-27年度的疫苗接种季生产XFG疫苗。目前美国已批准三种新冠疫苗使用，其中包括诺瓦瓦克斯的蛋白疫苗。诺瓦瓦克斯已于2024年将新冠疫苗授权给法国制药商赛诺菲，该交易价值至少12亿美元。市场预期，若FDA决定更新疫苗配方，诺瓦瓦克斯作为重要的疫苗供应商之一，可能从中获得新的商业机会，从而推动了股价的显著上涨。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["NVAX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1157177942","title":"Shah资本管理：坚信第二季度需回购1000万至2000万股诺瓦瓦克斯股票，以彰显对其科学与战略的信心并缓解历史稀释影响","url":"https://stock-news.laohu8.com/highlight/detail?id=1157177942","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1157177942?lang=zh_cn&edition=full","pubTime":"2026-05-15 20:23","pubTimestamp":1778847798,"startTime":"0","endTime":"0","summary":"Shah资本管理公司强调，诺瓦瓦克斯医药（NVAX）必须在今年第二季度进行规模在1000万至2000万股之间的股票回购。此举被视为管理层对公司核心科学实力与长期发展战略投下坚定信心票的关键行动。同时，该回购计划旨在积极应对并缓解因过往融资活动所带来的股权稀释效应，从而向市场传递更为明确的积极信号。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BK4585","BK4547","BK4568","NVAX","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1126402163","title":"Shah资本管理：新冠/流感联合疫苗三期试验须即刻启动，或借力赛诺菲，或依托诺瓦瓦克斯自身（创新合作模式）","url":"https://stock-news.laohu8.com/highlight/detail?id=1126402163","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1126402163?lang=zh_cn&edition=full","pubTime":"2026-05-15 20:23","pubTimestamp":1778847797,"startTime":"0","endTime":"0","summary":"Shah资本管理公司强调，针对新冠与流感的联合疫苗，其关键性的第三阶段临床试验必须立即启动。可行的路径包括通过赛诺菲进行合作，或由诺瓦瓦克斯医药自身主导并寻求创新性的合作伙伴关系。该公司认为，此举对于推进该重要疫苗的研发进程至关重要。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4547","BK4568","BK4585","BK4588","BK4139","NVAX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1197343258","title":"Shah资本管理：坚信诺瓦瓦克斯医药须在2026年实现盈利，需进一步削减包括SG&A和研发在内的开支——转向以AI为核心的运营","url":"https://stock-news.laohu8.com/highlight/detail?id=1197343258","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1197343258?lang=zh_cn&edition=full","pubTime":"2026-05-15 20:22","pubTimestamp":1778847739,"startTime":"0","endTime":"0","summary":"Shah资本管理公司近期发表观点，坚信诺瓦瓦克斯医药必须在2026年实现盈利。为实现这一目标，该公司认为诺瓦瓦克斯需要进一步削减运营支出，范围涵盖销售、一般及行政管理费用（SG&A）以及研发投入。关键在于，这些成本削减措施应伴随着运营模式的根本性转变，即向以人工智能为核心的高效运营体系迈进。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4547","BK4139","BK4588","BK4568","BK4585","NVAX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1123475443","title":"沙资本管理公司于2026年5月14日向诺瓦瓦克斯医药董事会提交演示文稿","url":"https://stock-news.laohu8.com/highlight/detail?id=1123475443","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1123475443?lang=zh_cn&edition=full","pubTime":"2026-05-15 20:20","pubTimestamp":1778847637,"startTime":"0","endTime":"0","summary":"2026年5月14日，沙资本管理公司向诺瓦瓦克斯医药（Novavax）董事会提交了一份演示文稿。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4585","BK4139","BK4568","BK4588","BK4547","NVAX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1194485217","title":"Shah资本管理：将在诺瓦瓦克斯医药6月18日股东会投票中，对五项提案均投反对票——SEC文件披露","url":"https://stock-news.laohu8.com/highlight/detail?id=1194485217","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1194485217?lang=zh_cn&edition=full","pubTime":"2026-05-15 20:20","pubTimestamp":1778847619,"startTime":"0","endTime":"0","summary":"根据一份提交给美国证券交易委员会（SEC）的文件，投资机构Shah资本管理公司表示，将在诺瓦瓦克斯医药于6月18日举行的股东投票中，对全部五项提案投出反对票。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4547","NVAX","BK4568","BK4588","BK4585","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1166301205","title":"异动解读 | 疫苗板块受莫德纳利好消息带动，诺瓦瓦克斯医药盘前大涨5.34%","url":"https://stock-news.laohu8.com/highlight/detail?id=1166301205","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1166301205?lang=zh_cn&edition=full","pubTime":"2026-05-11 21:29","pubTimestamp":1778506189,"startTime":"0","endTime":"0","summary":"诺瓦瓦克斯医药(NVAX)今日盘前股价大涨5.34%，引起了市场的广泛关注。消息面上，疫苗制造商莫德纳(MRNA)宣布与美国陆军传染病医学研究所合作，针对汉坦病毒开展了临床前研究，并且已与高丽大学签署研究协议，在其mRNA准入计划框架下合作开发汉坦病毒mRNA疫苗。这一利好消息带动了整个疫苗板块的上涨。作为疫苗板块的重要成员，诺瓦瓦克斯医药的股价也受到板块联动效应的影响而大幅上涨。同期，莫德纳股价盘前上涨9%，Inovio股价上涨11%，防护服制造商莱克兰工业和阿尔法普罗科技的股价也均上涨约6%，显示出市场对生物技术板块的积极情绪。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"7c550214a914aa5b0d6e74a203b21919","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["NVAX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1162351313","title":"异动解读 | 诺瓦瓦克斯医药盘中大涨17.96%，因第一季度营收远超预期","url":"https://stock-news.laohu8.com/highlight/detail?id=1162351313","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1162351313?lang=zh_cn&edition=full","pubTime":"2026-05-07 01:26","pubTimestamp":1778088408,"startTime":"0","endTime":"0","summary":"诺瓦瓦克斯医药（NVAX）今日盘中股价大幅上涨17.96%，引起了市场的广泛关注。消息面上，该公司公布的第一季度营收表现强劲，超出了华尔街分析师的普遍预期。根据报告，诺瓦瓦克斯第一季度营收达到1.395亿美元，远高于分析师平均预期的7830万美元，这主要得益于疫苗供应及授权协议带来的预付款和里程碑付款，有效抵消了市场需求疲软带来的压力。此外，公司管理层表示正持续推进降本增效计划，目标是在未来几年内大幅削减研发及行政费用，并维持了2026年的调整后营收预测。这些积极的财务表现和成本控制措施增强了投资者对公司未来发展的信心，推动了股价的显著上涨。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["NVAX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1140535232","title":"异动解读 | 股东敦促资本管理，诺瓦瓦克斯医药盘前大涨7.64%","url":"https://stock-news.laohu8.com/highlight/detail?id=1140535232","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1140535232?lang=zh_cn&edition=full","pubTime":"2026-04-08 18:39","pubTimestamp":1775644766,"startTime":"0","endTime":"0","summary":"诺瓦瓦克斯医药今日盘前大涨7.64%，引起了市场的广泛关注。消息面上，知名投资机构Shah Capital公开呼吁诺瓦瓦克斯医药采取积极资本管理措施，建议其尽快赎回2.25亿美元可转换债券，并考虑启动1000万至2000万股的股票回购计划。这一举措被市场解读为股东对提升公司估值的最新努力，通过优化资本结构、降低财务杠杆和传递股价被低估的信号，从而可能引发投资者积极反应。诺瓦瓦克斯医药作为疫苗研发领域的重要参与者，其资本运作动向备受关注。投资者正密切关注公司管理层是否会响应这一股东提案，以及后续可能采取的具体实施方案。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["NVAX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1138462511","title":"诺瓦瓦克斯医药盘前股价飙升6.1%；维权投资者Shah Capital宣布将投票反对公司高管薪酬及董事提名","url":"https://stock-news.laohu8.com/highlight/detail?id=1138462511","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1138462511?lang=zh_cn&edition=full","pubTime":"2026-04-08 18:07","pubTimestamp":1775642839,"startTime":"0","endTime":"0","summary":"诺瓦瓦克斯医药（NVAX）股价在盘前交易时段大幅上涨6.1%，引发市场关注。与此同时，知名维权投资机构Shah Capital公开表示，将在公司即将举行的股东大会上对高管薪酬方案及董事会候选人名单投下反对票。\n这一股价异动与股东积极行动同时出现，凸显了市场对诺瓦瓦克斯医药公司治理状况的高度关注。Shah Capital作为长期关注公司治理的活跃投资者，此次采取反对立场可能影响其他机构投资者的投票决策。\n目前，诺瓦瓦克斯医药尚未就此事发表官方评论。市场分析师指出，此类股东行动通常反映了投资者对公司战略方向或管理层表现的不满，可能促使公司重新评估其治理结构。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BK4585","BK4547","BK4568","NVAX","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1185735364","title":"Shah Capital敦促诺瓦瓦克斯医药赎回2.25亿美元可转债及/或启动1000万至2000万股回购计划","url":"https://stock-news.laohu8.com/highlight/detail?id=1185735364","media":"美股速递","labels":["shareholding","buyback"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1185735364?lang=zh_cn&edition=full","pubTime":"2026-04-08 18:00","pubTimestamp":1775642419,"startTime":"0","endTime":"0","summary":"知名投资机构Shah Capital近日公开呼吁生物技术公司诺瓦瓦克斯医药采取积极资本管理措施，建议其尽快赎回市场上流通的2.25亿美元可转换债券，同时考虑启动规模达1000万至2000万股的股票回购计划。通过削减债务规模和回购股份，诺瓦瓦克斯医药有望优化资本结构，进一步提升每股收益指标。值得注意的是，诺瓦瓦克斯医药作为疫苗研发领域的重要参与者，其资本运作动向备受关注。Shah Capital的建议若被采纳，可能引发连锁市场反应。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding,buyback","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NVAX","BK4139","BK4568","BK4547","BK4585","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1162099302","title":"诺瓦瓦克斯医药上调2026年调整后营收预期，受疫苗交易强劲表现提振","url":"https://stock-news.laohu8.com/highlight/detail?id=1162099302","media":"老虎资讯综合","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1162099302?lang=zh_cn&edition=full","pubTime":"2026-02-26 23:07","pubTimestamp":1772118465,"startTime":"0","endTime":"0","summary":"周四， $诺瓦瓦克斯医药$ 上调了其2026年调整后营收预测，称预计来自疫苗供应和授权协议的里程碑付款将抵消需求疲软带来的压力。这家生物科技公司目前预计，2026年调整后营收将在2.30亿美元至2.70亿美元之间，高于此前预计的1.85亿美元至2.05亿美元。Novavax预计将在2028年前实现盈利，主要受益于其与Sanofi合作协议中的关键产品上市，包括一款采用其Nuvaxovid疫苗的COVID-流感二联疫苗。受消息影响， $诺瓦瓦克斯医药$ 升19%。","market":"us","thumbnail":"https://static.tigerbbs.com/fb4be1ff4aaa40ac88564f80f173158e","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/fb4be1ff4aaa40ac88564f80f173158e"],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":"59d2b24cafa113cadc65f4c13bf874dc","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"1","news_top_title":"诺瓦瓦克斯医药上调2026年调整后营收预期，受疫苗交易强劲表现提振","news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NVAX","LABD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1191168252","title":"诺瓦瓦克斯医药CEO谈即将召开的CDC ACIP会议：“已确定召开，这是好消息，我们将密切关注”","url":"https://stock-news.laohu8.com/highlight/detail?id=1191168252","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1191168252?lang=zh_cn&edition=full","pubTime":"2026-02-26 22:53","pubTimestamp":1772117621,"startTime":"0","endTime":"0","summary":"诺瓦瓦克斯医药首席执行官对即将举行的美国疾病控制与预防中心免疫实践咨询委员会会议发表评论，称会议日程已确定，这是一个积极信号，公司方面将予以高度关注。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4588","BK4139","BK4547","BK4568","BK4585","NVAX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1193975080","title":"异动解读 | 诺瓦瓦克斯医药盘前大跌9.76%，CEO警告宏观与监管环境带来重大不确定性","url":"https://stock-news.laohu8.com/highlight/detail?id=1193975080","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1193975080?lang=zh_cn&edition=full","pubTime":"2026-02-26 21:44","pubTimestamp":1772113479,"startTime":"0","endTime":"0","summary":"诺瓦瓦克斯医药(NVAX)今日盘前股价大跌9.76%，引发了市场关注。消息面上，公司首席执行官公开指出，美国当前面临的宏观经济形势与监管环境，正为疫苗企业带来显著的不确定性。这一表态直接加剧了投资者对于诺瓦瓦克斯医药未来运营压力与增长前景的担忧，可能是导致股价在盘前交易时段承压下跌的主要原因。","market":"nz","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["NVAX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1123126799","title":"诺瓦瓦克斯医药CEO：美国当前宏观与监管环境为疫苗公司带来重大不确定性","url":"https://stock-news.laohu8.com/highlight/detail?id=1123126799","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1123126799?lang=zh_cn&edition=full","pubTime":"2026-02-26 21:42","pubTimestamp":1772113334,"startTime":"0","endTime":"0","summary":"诺瓦瓦克斯医药首席执行官指出，美国当前面临的宏观经济形势与监管环境，正为疫苗企业带来显著的不确定性。这一表态凸显了行业在复杂外部环境下所承受的运营压力。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NVAX","BK4585","BK4568","BK4547","BK4139","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2606775920","title":"诺瓦瓦克斯医药盘中异动 早盘大幅拉升5.09%报10.12美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2606775920","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2606775920?lang=zh_cn&edition=full","pubTime":"2026-01-27 22:46","pubTimestamp":1769525177,"startTime":"0","endTime":"0","summary":"北京时间2026年01月27日22时46分，诺瓦瓦克斯医药股票出现异动，股价大幅拉升5.09%。截至发稿，该股报10.12美元/股，成交量112.865万股，换手率0.69%，振幅4.05%。诺瓦瓦克斯医药股票所在的生物技术行业中，整体涨幅为0.94%。其相关个股中，Biomx Inc.、阿诺医药、Acumen Pharmaceuticals, Inc.涨幅较大，Biomx Inc.、Vyome Holdings, Inc.、Genenta Science Spa较为活跃，换手率分别为756.87%、687.03%、215.81%，振幅较大的相关个股有Biomx Inc.、Genenta Science Spa、Kazia Therapeutics Limited，振幅分别为53.90%、25.38%、21.94%。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2026012722461797a3a3c5&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2026012722461797a3a3c5&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4588","BK4547","NVAX","BK4568","BK4585","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2604147291","title":"诺瓦瓦克斯（Novavax）股价上涨3.5%","url":"https://stock-news.laohu8.com/highlight/detail?id=2604147291","media":"每日经济新闻","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2604147291?lang=zh_cn&edition=full","pubTime":"2026-01-20 22:57","pubTimestamp":1768921028,"startTime":"0","endTime":"0","summary":"每经AI快讯，1月20日，诺瓦瓦克斯（Novavax）与辉瑞（Pfizer）签署疫苗研发许可协议后，其股价上涨3.5%。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202601203625027339.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202601203625027339.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK4588","BK4547","BK4568","BK4585","NVAX","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2605108778","title":"诺瓦瓦克斯医药与辉瑞达成非独家许可协议","url":"https://stock-news.laohu8.com/highlight/detail?id=2605108778","media":"动脉网","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2605108778?lang=zh_cn&edition=full","pubTime":"2026-01-20 21:56","pubTimestamp":1768917360,"startTime":"0","endTime":"0","summary":"1月20日消息，诺瓦瓦克斯医药与辉瑞达成非独家许可协议，允许辉瑞在多达两个疾病领域应用诺瓦瓦克斯医药的Matrix-M佐剂，该佐剂可增强疫苗免疫反应。通过此次合作，诺瓦瓦克斯医药不仅将获得3000万美元的预付款，后续还有机会根据开发和销售情况，额外获得最高达5亿美元的里程碑付款。此次合作有望推动疫苗研发创新，为全球公共卫生事业带来积极影响。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260120215811a44166bb&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260120215811a44166bb&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["NVAX","SG9999003800.SGD","LU0058720904.USD","SG9999001176.USD","IE000M9KFDE8.USD","LU0306806265.USD","LU0985481810.HKD","LU1066051498.USD","LU1066053197.SGD","PFE","SG9999011175.SGD","LU1894683264.USD","LU0225284248.USD","LU0122379950.USD","IE00BBT3K403.USD","LU0234572021.USD","IE00BLSP4452.SGD","IE0002270589.USD","LU0456855351.SGD","LU1023059063.AUD","SG9999013999.USD","BK4599","LU1894683348.USD","BK4581","IE00B19Z3B42.SGD","BK4550","BK4007","IE00BLSP4239.USD","LU0170899867.USD","SG9999001176.SGD","LU0321505868.SGD","SG9999002224.SGD","BK4568","BK4585","BK4588","LU1057294990.SGD","LU0306807586.USD","SGXZ57979304.SGD","BK4533","BK4547","LU0225771236.USD","LU1883839398.USD","LU0289739699.SGD","BK4534","BK4592","LU0321505439.SGD","LU0868494617.USD","IE00B19Z3581.USD","BK4139","SG9999002232.USD"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.novavax.com","stockEarnings":[{"period":"1week","weight":-0.1798},{"period":"1month","weight":-0.1474},{"period":"3month","weight":-0.1936},{"period":"6month","weight":0.2789},{"period":"1year","weight":0.157},{"period":"ytd","weight":0.2827}],"compareEarnings":[{"period":"1week","weight":-0.0255},{"period":"1month","weight":0.0022},{"period":"3month","weight":0.0916},{"period":"6month","weight":0.0751},{"period":"1year","weight":0.2338},{"period":"ytd","weight":0.084}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"Novavax, Inc.于1987年根据美国特拉华州法律注册成立，是一家临床阶段的生物制药公司，专注于重组纳米颗粒疫苗和佐剂的发现、开发和商业化。该公司的疫苗技术平台基于包括病毒样颗粒（VLP）和蛋白质纳米颗粒候选疫苗的专有重组纳米颗粒疫苗技术。该公司的候选疫苗是基因工程的三维纳米结构，其中包含了免疫学上重要的蛋白质。公司的疫苗产品管线针对多种传染病，候选药物目前处于呼吸道合胞病毒（RSV）、季节性流感、大流行性流感的临床开发阶段。此外，该公司在印度的合资公司CPL Biologics Private Limited（CPLB）正在积极开发多款候选疫苗，这些候选疫苗由诺瓦瓦克斯医药进行基因工程改造。","yearOnYearQuotes":[{"month":1,"riseRate":0.677419,"avgChangeRate":0.108114},{"month":2,"riseRate":0.580645,"avgChangeRate":0.042802},{"month":3,"riseRate":0.258065,"avgChangeRate":-0.045948},{"month":4,"riseRate":0.451613,"avgChangeRate":0.007887},{"month":5,"riseRate":0.548387,"avgChangeRate":0.134336},{"month":6,"riseRate":0.483871,"avgChangeRate":0.080543},{"month":7,"riseRate":0.566667,"avgChangeRate":0.019422},{"month":8,"riseRate":0.533333,"avgChangeRate":0.039885},{"month":9,"riseRate":0.5,"avgChangeRate":-0.036425},{"month":10,"riseRate":0.3,"avgChangeRate":0.027361},{"month":11,"riseRate":0.333333,"avgChangeRate":-0.003351},{"month":12,"riseRate":0.366667,"avgChangeRate":-0.038609}],"exchange":"NASDAQ","name":"诺瓦瓦克斯医药","nameEN":"Novavax"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.43.1","shortVersion":"4.43.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"诺瓦瓦克斯医药(NVAX)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供诺瓦瓦克斯医药(NVAX)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"诺瓦瓦克斯医药,NVAX,诺瓦瓦克斯医药股票,诺瓦瓦克斯医药股票老虎,诺瓦瓦克斯医药股票老虎国际,诺瓦瓦克斯医药行情,诺瓦瓦克斯医药股票行情,诺瓦瓦克斯医药股价,诺瓦瓦克斯医药股市,诺瓦瓦克斯医药股票价格,诺瓦瓦克斯医药股票交易,诺瓦瓦克斯医药股票购买,诺瓦瓦克斯医药股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"诺瓦瓦克斯医药(NVAX)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供诺瓦瓦克斯医药(NVAX)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}